Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Unlock Full MRNA Analysis
UpgradeKey Numbers
Market Cap
$40B
P/E
N/A
Revenue Growth
-50.0%
Gross Margin
N/A
ROE
N/A
About Moderna Inc.
Listed on the NASDAQ, Moderna Inc. operates as a mid-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. mRNA platform company expanding beyond COVID into cancer and rare diseases. With a $40B market capitalization and no current profitability, the business is characterized by top-line contraction, reporting -50% revenue change year-over-year.
Expert Coverage
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.